Ns Pharma Inc.
- Address
- 140 East Ridgewood Avenue Suite 280s
Sponsor Overview
Specializations
Duchenne Muscular Dystrophy
Clinical research activity in neuromuscular disease includes studies of viltolarsen in boys with Duchenne Muscular Dystrophy, with attention to treatment tolerability and disease-focused care in a pediatric population.
- Neuromuscular disorders
- Pediatric genetic disease
- Muscle degeneration
The sponsor’s work in this area centers on a rare inherited condition that affects skeletal muscle function and mobility.
Eosinophilic Granulomatosis with Polyangiitis
Research in autoimmune vasculitis includes evaluation of NS 229 in Eosinophilic Granulomatosis with Polyangiitis, reflecting interest in inflammatory disease control and remission outcomes.
- Systemic vasculitis
- Eosinophilic inflammation
- Immune-mediated disease
This therapeutic area addresses a rare multisystem disorder involving both vascular inflammation and eosinophil-driven pathology.
Rare Disease Therapeutics
The sponsor’s portfolio spans orphan disease research with a focus on conditions that require specialized clinical development in small patient populations.
- Rare inherited disorders
- Rare inflammatory diseases
- Targeted therapeutic development
These programs involve treatment areas where unmet medical need is high and disease-specific intervention is central to care.
Pediatric and Multinational Clinical Research
Active studies extend across multiple countries and research sites, including trials involving children and patients with chronic, specialist-managed disease.
- Pediatric clinical research
- International trial participation
- Specialty disease management
The sponsor’s research landscape includes both neuromuscular and inflammatory indications with geographically distributed clinical activity.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety Evaluation of Methyl-(1-{[6-{[(1S)-1-Cyclopropylethyl]amino}-2-(pyrazolo[5,1-b][1,3]thiazol-7-yl)-pyrimidin-4-yl]carbonyl}piperidin-4-yl)carbamate-Mono(4-methylbenzenesulfonate) Monohydrate in Eosinophilic Granulomatosis with Polyangiitis |  France Germany Italy Spain | Recruiting |
| Phase 3 Open-Label Extension Study on Viltolarsen Safety and Efficacy in Ambulatory Male Patients with Duchenne Muscular Dystrophy |  Czechia Greece Italy Norway Spain The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 19 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune System Diseases1 trial322 other sponsors
- 2.Musculoskeletal Diseases1 trial238 other sponsors
Partnered Research Centres
19 centres- Address
- Largo Medaglie D'oro 9, 38122 Trento
- Address
- 151 Route De Saint Antoine, 06200 Nice
- Address
- Piazzale Ludovico Antonio Scuro 10, 37134 Verona
- Address
- Sokolska 581, Novy Hradec Kralove, 500 03 Novy Hradec Kralove
- Address
- Largo Francesco Vito 1, 00168 Rome
- Address
- Paseo De La Castellana 261, 28046 Madrid
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Ns Pharma Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.